Details

Autor(en) / Beteiligte

• Yoshimura, Akihiro
• Yamada, Tadaaki
• Okura, Naoko
• Takeda, Takayuki
• Hirose, Kazuki
• Kubota, Yutaka
• Shiotsu, Shinsuke
• Hiranuma, Osamu
• Chihara, Yusuke
• Tamiya, Nobuyo
• Kaneko, Yoshiko
• Uchino, Junji
• Takayama, Koichi

Titel

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation

Ist Teil von

• Cancers, 2019-03, Vol.11 (3), p.365

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2019

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung cancer (NSCLC) in patients with the -T790M mutation, who are resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, the factors affecting response to osimertinib treatment are unknown. In this retrospective study, 27 NSCLC patients with the -T790M mutation were enrolled at five institutions in Japan. Among several parameters tested, the progression-free survival (PFS) associated with the initial EGFR-TKIs was positively correlated with the PFS after osimertinib treatment ( = 0.021). The median PFS following osimertinib treatment and the overall survival (OS) were longer in patients who responded to osimertinib than in those who did not (17.7 months versus 3.5 months, = 0.009 and 24.2 months versus 13.5 months, = 0.021, respectively). A multivariate analysis demonstrated that the PFS with initial EGFR-TKIs was significantly related to the PFS with osimertinib treatment ( = 0.035), whereas osimertinib response was significantly related to the PFS and OS with osimertinib treatment ( = 0.016 and = 0.006, respectively). Our retrospective observations indicate that PFS following the initial EGFR-TKI treatment and the response rate to osimertinib might be promising predictors for effective osimertinib treatment in NSCLC patients with the -T790M mutation.